Monitor this situation.
Unsubscribe anytime.
[SITUATION] · [ACTIVE] · [BUSINESS]
2 clusters · 2 sources · 21 days · First seen · Last updated
US FDA inspections of Zydus Lifesciences facilities
Overview
The US Food and Drug Administration (FDA) has conducted multiple inspections of manufacturing sites operated by Zydus Lifesciences, resulting in several regulatory observations.
In October 2026, inspections at the company’s Moraiya plant in Gujarat, India, led to five observations. These included discrepancies in quality lab records, insufficient investigations into unexplained results, and failures to identify root causes for off-trend product results.
In November 2026, the FDA concluded an inspection of the LiqMeds facility in Weedon, United Kingdom, which is operated by Zydus Lifesciences. This inspection resulted in four observations. The company has stated its intention to work with the regulator to address these findings.
Entities
US Food and Drug Administration · Zydus Lifesciences · Goa · United States · Lupin
Timeline
-
[BUSINESS] 2 sourcesUSFDA issues four observations following inspection of Zydus LiqMeds facility in UK
The USFDA concluded an inspection of Zydus Lifesciences' LiqMeds facility in the UK with four observations. The site supplies oral liquid pharmaceuticals to the UK and US markets.
-
[BUSINESS] 2 sourcesUS FDA issues observations following inspections of Indian drugmakers
The US FDA issued five observations at Zydus Lifesciences’ Moraiya plant and one observation at Lupin’s Goa facility following recent inspections of the Indian drugmakers' manufacturing sites.
Sources
medicaldialogues.in · news18.com